Industry Tightens Drug Pricing Message, But Loose Ends Remain
Executive Summary
Drug makers are under increasing pressure regarding the cost of their medicines, but instead of pointing fingers at payers for patients' out-of-pocket costs, the industry has shifted to a more collaborative tone, although some tensions will take time to overcome.
You may also be interested in...
Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Lilly’s new CEO David Ricks said he had confidence in the Trump Administration’s ability to understand and respond to the biopharma industry’s needs as well as address drug pricing concerns. The company’s fourth quarter earnings could insulate it from cost criticism, since sales volume drove revenue gains, not prices.
2Q Pharma Results Preview: What Lies Ahead
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
BIO 2016 Notebook: Pricing And Innovation Hot Topics In San Francisco
Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.